Technical Analysis for NLNK - NewLink Genetics Corporation

Grade Last Price % Change Price Change
grade D 1.91 -7.73% -0.16
NLNK closed down 7.73 percent on Friday, March 22, 2019, on 1.15 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Flat
See historical NLNK trend table...

Date Alert Name Type % Chg
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 21 Calm After Storm Range Contraction -7.73%
Mar 21 Upper Bollinger Band Walk Strength -7.73%
Mar 21 Wide Bands Range Expansion -7.73%
Mar 21 Upper Bollinger Band Touch Strength -7.73%
Mar 20 Jack-in-the-Box Bullish Bullish Swing Setup -10.33%

Older signals for NLNK ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company's lead product candidate, HyperAcute Pancreas cancer immunotherapy, is being studied in two Phase III clinical trials in surgically-resected pancreatic cancer patients. It is also developing HyperAcute Lung, which is being studied in a multi-center randomized, controlled Phase IIB/III clinical trials for non-small cell lung cancer; HyperAcute Melanoma that is in Phase II clinical trials for the treatment of melanoma; and a HyperAcute Renal cell cancer immunotherapy, as well as HyperAcute prostate and HyperAcute breast product candidates. In addition, the company is developing Indoximod, a small-molecule, orally bioavailable product candidate, which is being evaluated for the treatment of metastatic solid tumors in two Phase IB/II clinical trials; Provenge Indoximod that is in Phase II clinical trials for the treatment of prostate cancer; Docetaxel Indoximod, which is in Phase II clinical trials for the treatment of metastatic breast cancer; HyperAcute immunotherapy plus Indoximod that is in Phase IIB clinical trials; and NLG-919 IDO Pathway Inhibitor Candidate, which is in Phase I clinical trials for the treatment of metastatic solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Immunotherapy Prostate Cancer Cancer Immunotherapy Non Small Cell Lung Cancer Melanoma Cancer Treatment Metastatic Breast Cancer Bemcentinib Cancer Vaccine Treatment Of Prostate Cancer Metastatic Solid Tumors Treatment Of Metastatic Breast Cancer Immunotherapeutic Products Immunotherapy Technology Treatment Of Melanoma
Is NLNK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.77
52 Week Low 1.28
Average Volume 477,766
200-Day Moving Average 2.5981
50-Day Moving Average 1.6383
20-Day Moving Average 1.822
10-Day Moving Average 1.914
Average True Range 0.1476
ADX 33.45
+DI 27.8593
-DI 15.2219
Chandelier Exit (Long, 3 ATRs ) 1.8272
Chandelier Exit (Short, 3 ATRs ) 2.0228
Upper Bollinger Band 2.1134
Lower Bollinger Band 1.5306
Percent B (%b) 0.65
BandWidth 31.986828
MACD Line 0.1064
MACD Signal Line 0.0878
MACD Histogram 0.0187
Fundamentals Value
Market Cap 56.19 Million
Num Shares 29.4 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.83
Price-to-Sales 6.79
Price-to-Book 2.71
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.22 2.16 2.15
Resistance 2 (R2) 2.16 2.08 2.14 2.13
Resistance 1 (R1) 2.03 2.04 2.00 2.01 2.12
Pivot Point 1.97 1.97 1.95 1.95 1.97
Support 1 (S1) 1.84 1.89 1.81 1.82 1.70
Support 2 (S2) 1.78 1.85 1.76 1.69
Support 3 (S3) 1.65 1.78 1.67
Support 4 (S4) 1.63